Signaling pathways control cell-fate decisions that ultimately determine the behavior of cancer cells.
Introduction
Traditional cancer biomarkers are based upon an association between clinical parameters and the expression or mutation of specific genes, often combined into panels to strengthen their sensitivity and specificity. Although these biomarkers have extensive clinical utility, they frequently lack any mechanistic anchoring to the fundamental cellular processes responsible for tumorigenesis or therapeutic response. Signaling pathways play a key role in these processes; therefore, analysis of the activity of signaling pathways should aid in the development of biomarkers linked to cellular function. However, it is technically challenging to observe the activation of these pathways during the process of tumor formation or therapeutic treatment. We, therefore, hypothesized that simulating the potential of cancer cells to activate a central signaling pathway under these conditions may provide insight into the prognostic information contained within these pathways.
Focusing upon the c-Jun N-terminal Kinase (JNK) pathway, because this pathway mediates apoptotic cell death induced by both physiological stress and therapeutic agents, we sought to develop a model of the JNK pathway that could correlate patient-specific JNK response dynamics with survival data.
Although the identities of the kinases that activate JNK are well known (1) , this signaling pathway displays dynamic behavior suggestive of a complex network structure that belies a simple linear kinase
Results

Ultrasensitive JNK activation and apoptosis in neuroblastoma cells exposed to stress
Consistent with a tumor-suppressive role for JNK signaling in response to stress within the tumor microenvironment, we observed that JNK inhibition increased tumor growth by ~3-fold in a zebrafish model of MYCN-driven, spontaneous neuroblastoma (23) (Fig. 1A) . This proapoptotic role of JNK also occurred in the SH-SY5Y neuroblastoma cell line, in which a JNK inhibitor dampened the apoptotic response to various stress conditions ( Fig. 1B) and significantly reduced stress-dependent p53 accumulation and caspase-3 cleavage (Fig. S1A ) triggered by physiological or drug-induced stress. We observed this reduction in apoptotic response in SH-SY5Y cells using agents that inhibit protein translation (anisomycin) to produce ribotoxic stress, inhibit mitochondrial function (rotenone) to produce oxidative stress, cause DNA damage (doxorubicin) to produce genotoxic stress, or disrupt microtubules (vincristine) to cause cell cycle arrest (Fig. 1B, fig. S1A ). Two of these are drugs used for neuroblastoma treatment: Doxorubicin is used to treat intermediate-risk neuroblastoma patients, and vincristine is used in combination therapy for high-risk neuroblastoma patients (19) .
To determine whether the apoptotic, ultrasensitive mode of JNK activation occurs in neuroblastoma cells, we exposed SH-SY5Y cells to increasing concentrations of anisomycin for 30 minutes (Fig. 1C) , which we found, with an antibody that recognizes all of the three JNK isoforms JNK1, JNK2, and JNK3 (also known as MAPK8, MAPK9, MAPK10) phosphorylated in the activation loop (pJNK T183/Y185 ), was the time point representing the maximal abundance of this phosphorylated and active form of JNK (fig. S1B,C). Anisomycin induced ultrasensitive JNK activation, with pJNK T183/Y185 increasing from basal to saturated amounts within one order of magnitude change in anisomycin concentration. We explored the response of two other MAPKs to anisomysin, the stress-activated kinase p38 and extracellular signalregulated kinase (ERK) 1 and ERK2 (collectively referred to as ERK). In contrast to the change in the abundance of pJNK T183/Y185 , the abundance of activation loop-phosphorylated p38 (pP38 T180/Y182 ) increased over a broader concentration range, and the weak increase in activation loop-phosphorylated pERK T202/Y204 slowly approached saturation. The Hill exponent (H) for JNK activation, which quantifies ultrasensitivity of the response, was greater than that observed for either p38 or ERK activation (Fig. 1C ).
Importantly, the abundance of total JNK, p38, and ERK did not change under these conditions ( fig. S1D ). Additionally, a p38 inhibitor had no effect upon apoptosis induced under any of the tested conditions ( fig. S1E ), indicating that switch-like activation in response to stress was a distinctive aspect of the apoptotic JNK pathway in SH-SY5Y cells under these conditions.
Identifying the components of the JNK network in neuroblastoma cells
The network structure that mediates this behavior of JNK is uncharacterized in neuroblastoma, but could arise through positive feedback from JNK to upstream components of the pathway. To investigate the existence of JNK-mediated positive feedback, we experimentally disrupted that loop using a JNK inhibitor and measured the activation-loop phosphorylation of MKK4 and MKK7 in response to increasing anisomycin concentration ( Fig. 1D ). In the presence of a JNK inhibitor, activation of JNK and MKK7 (detected as the forms phosphorylated in the activation loops) by anisomycin was significantly reduced and no longer resembled a high-amplitude ultrasensitive response, whereas the activation-loop phosphorylation of MKK4 was less affected. Importantly, the abundance of MKK4, MKK7 and JNK did not change under these conditions (fig. S1D). We also observed similar changes in response to anisomycin when the cells were exposed to the structurally unrelated JNK inhibitor VIII (fig. S2A) or in cells exposed to the osmotic-stress agent sorbitol in the presence or absence of JNK inhibitor II ( fig.   S2B ). This positive influence of JNK activity upon its own upstream kinases conforms to our hypothesis of a JNK-mediated positive feedback loop that is activated during cell stress.
To ascertain the contribution of MKK4 and MKK7 (1), to JNK activation in neuroblastoma cells, we To develop a model of the JNK network, we needed to identify the MAPKKK upstream of MKK4 and MKK7. ZAK is a MAPKKK that mediates anisomycin stimulation of the JNK pathway in other cell types (24, 25) . ZAK knockdown in SH-SY5Y cells inhibited the activation of JNK, MKK4, and MKK7 by anisomycin and the other stressors ( Fig. 1E ), but did not alter the total amount of JNK, MKK4 or MKK7 ( Fig. S2D ). Stable ZAK knockdown also increased the concentration at which 50% of the cells died (IC 50 ) for vincristine ~3 fold and for doxorubicin ~10 fold ( fig. S2E ), further suggesting that the ZAK-MKK4/MKK7-JNK signaling axis is central to the cytotoxic response of neuroblastoma cells to therapeutic agents.
Scaffolding proteins, such as the JNK-interacting protein (JIP) family, can contribute to switch-like JNK signaling through the colocalization of MAPKKK-MAPKK-MAPK modules (26) . However, we could not detect JIP1 or JIP4 in SH-SY5Y cells, and knocking down JIP2 or JIP3 by siRNA had no effect on anisomycin-induced JNK activity ( fig. S3A ). Although we did not detect a role for the JIP scaffold family, we investigated protein-protein interactions within this kinase network. ZAK can activate JNK through both MKK4 and MKK7 (27) . Following activation, dimerization, and autophosphorylation, ZAK interacts directly with MKK7 (28) .
To test for protein interactions, we expressed tagged ZAK with either tagged JNK2 or tagged MKK7 in SH-SY5Y cells. Although we coimmunoprecipitated enhanced green fluorescent protein (EGFP)-tagged ZAK and endogenous MKK7 ( fig. S3B ), MKK4 and EGFP-ZAK did not coimmunoprecipitate ( fig. S3B ).
JNK tagged with the V5 epitope coiummunoprecipitated with EGFP-ZAK ( fig. S3C ). Knockdown of MKK7 did not reduce the coimmunoprecipitation of EGFP-ZAK and JNK-V5 ( fig. S3D ). JNK docks to substrates by binding D-domains. ZAK has many putative D-domains [based upon the (K/R) 1-3 X 1-6 (L/I)X(L/I) consensus sequence for JNK binding (29) ] and one or more of these putative D-domains may enable ZAK to interact directly with JNK]. Given that we did not detect any involvement of JIPs, the coimmunoprecipitation data suggest the possibility that ZAK may act as a scaffold for MKK7 and JNK.
Identifying positive feedback from JNK to MKK7
Because the known JNK scaffolds were not involved in JNK activation in this system, we tested whether JNK-mediated feedback phosphorylation of its upstream kinases was responsible for ultrasensitive JNK activation. We utilized MAPK substrate motif antibodies (pTP and PxpSP/pSPxR/K) to investigate potential JNK-dependent phosphorylation events on MKK4, MKK7 and ZAK by Western blotting.
Indeed, EGFP-MKK4 and EGFP-MKK7 underwent anisomycin-stimulated and JNK-dependent phosphorylation at TP motifs, and MKK4 was also phosphorylated at PxSP or SPxR/K motifs ( Fig. 2A ).
The amount of ZAK phosphorylated at TP motifs was unaffected by anisomycin. Because the observed positive feedback loop appeared to act predominantly on MKK7 ( Fig. 1D ), we focused on feedback phosphorylation of MKK7 by JNK. We mutated Thr 66 and Thr 83 within TP motifs in MKK7, because they flank a D-domain, through which JNK docks to phosphorylate substrates (29) . Both mutations significantly impaired anisomycin-induced phosphorylation of MKK7 at TP motifs, with the T66A mutation having a larger effect ( Fig. 2B ).
To further investigate the mechanism underlying this JNK-mediated positive feedback, we utilized the murine MKK7β1 isoform, in which Thr 66 and Thr 83 are conserved, and the murine MKK7α1 isoform, which lacks the N-terminal region (Ala 2 -His 88 ) that contains these feedback phosphosites. We confirmed that FLAG-tagged murine MKK7β1, but not MKK7α1, was phosphorylated in a JNK-dependent manner in response to anisomycin when expressed in SH-SY5Y cells (Fig. 2C ). Mutation of Thr 66 , but not Thr 83 , within MKK7β1 significantly reduced anisomycin-induced MKK7 activation-loop phosphorylation (Ser 271 ), confirming that this site constitutes the positive feedback from JNK to MKK7 (Fig. 2D ). In contrast, the MKK7α1 isoform, which cannot undergo JNK-mediated feedback phosphorylation, displayed significantly increased basal activation loop phosphorylation, which did not change upon anisomycin treatment ( Fig. 2D ).
Another possible mechanism for the feedback could be an enhanced interaction between ZAK and MKK7. However, the coimmunoprecipitation between ZAK and MKK7 was retained in the MKK T66A or T83A mutants, indicating that feedback phosphorylation from JNK to MKK7 did not affect the binding of MKK7 to ZAK ( Fig. 2E ). These protein-interaction data and the phosphorylation analysis indicated that the N-terminal region of MKK7 may be an autoinhibitory domain and that inhibition is relieved upon JNK-mediated phosphorylation, thereby providing a mechanistic basis for the observed positive feedback loop within the JNK network.
AKT-mediated crosstalk to JNK
Another network connection capable of regulating JNK activation is AKT-mediated inhibitory phosphorylation of MKK4 at Ser 80 (30) . To explore the crosstalk between AKT and JNK signaling in SH- 
Mathematical modelling of the JNK network dynamics
To generate quantitative predictions using this experimentally resolved network structure, we built, calibrated, and validated a computational model of JNK network dynamics ( Fig. 4A ). This model is based on ordinary differential equations (ODEs) and incorporates the following experimentally confirmed features. First, stress activates ZAK, which activates the two MKK4 and MKK7, which in turn activate JNK. Second, there is a positive feedback from JNK to MKK7 and inhibitory crosstalk from AKT to MKK4 and MKK7. Third, ZAK functions as both a kinase and a scaffold that binds MKK7 and JNK. The scaffold-mediated interactions, double reversible phosphorylation cycles in the MAPK cascade, and AKT crosstalk result in a combinatorial increase of feasible reactions and multiple states of the JNK network kinases (32, 33) . Therefore, we built the model using rule-based modelling (34) (35) (36) (37) , which develops the ODEs on the basis of a framework of rules describing the reactions and states of the system. Constructed in this fashion, the model implemented 23 rules, which resulted in 258 reactions and 36 parameters (table S1). The rule-based approach minimizes the number of necessary simplifying assumptions, and, although increasing the number of states and reactions, it does not increase the number of parameters in the model.
To generate quantitative predictions, we calibrated the model using our timecourse ( fig. S1C ), doseresponse (Fig.1C ), and MAPKK knockdown data ( Fig. 1E ). We adjusted key parameters, such as the kinase activities and feedback strengths, using a global parameter estimation method called adaptive simulated annealing (38) . To assess the associated uncertainty, we adopted a Monte-Carlo based approach by randomly changing the initial parameters 50 times and refitting the model (table S2, text S1: Dynamic modelling of the JNK network) (39, 40) . We then analyzed parameter correlations and variability of the simulated predictions. Although the parameter estimates have large standard deviations, the estimates do not spread over the entire multidimensional space, but occupy structured regions where some parameter values are correlated ( fig. S4A ,B,C). Even though exact parameter values cannot be identified, the predictions are accurate and tight for all these estimates ( Fig. 4C ).
Experimental model validation
Model simulations performed to simulate the presence of a JNK inhibitor recapitulated our experimental observations of a positive feedback loop, in that blocking the positive feedback from JNK to MKK7 impaired the stress response and its switch-like, ultrasensitive behavior ( Fig. 4B , middle column). We further tested the predictive power of the model by examining the potential scaffolding effect of ZAK ( Fig. 4C , left), using an independent validation data set ( Fig. 4C , middle and right). Simulations predicted that ZAK overexpression would impair JNK activation due to the inability of ZAK, when in excess, to simultaneously scaffold both MKK7 and JNK. Additionally, these simulations predicted that ZAK overexpression would further impair JNK activation following MKK4 knockdown, but not MKK7 knockdown. In support of our experimentally resolved network structure, these model predictions were fully corroborated by experimental analysis of anisomycin-mediated JNK activation following the simultaneous overexpression of ZAK and knockdown of either MKK4 or MKK7 ( Fig. 4C) . Initially, our model calibration and validation experiments were performed in SH-SY5Y cells, using anisomycin as a stressor. We, therefore, tested whether the model correctly predicted the JNK response to different stress-inducing agents and in other neuroblastoma cell lines. To that end, we measured the abundance of each kinase included in the model and the phosphorylation of Akt S473 in the SMS-KCN and IMR32 lines relative to their amounts in the SH-SY5Y line (Fig. 4D , left). We then populated our original model with these values as parameters, thereby generating three cell line-specific models. Simulations predicted that the JNK response would be markedly impaired in SMS-KCN cells and almost absent in IMR32 cells ( Fig. 4D , right). The predicted differences in the JNK pathway activity (JNK activation-loop phosphorylation) among the three cell lines in response to stress were confirmed experimentally for treatment with vincristine ( Fig. 4E ), thus demonstrating that our model can be used to simulate and correctly predict the JNK response in different neuroblastoma cell lines and across different stress stimuli.
Furthermore, both the observed and predicted JNK response for each cell line was proportional to the apoptotic response induced by vincristine ( Fig. 4F ), suggesting that our model also possesses predictive power with regard to the biological response of neuroblastoma cells to clinically relevant therapeutic agents.
Prognostic utility of the JNK model
On the basis of our combined experimental and modeling studies, we hypothesised that a high amplitude, ultrasensitive JNK stress response would promote apoptosis in neuroblastoma cells, and would, therefore, be associated with a better patient prognosis than a low amplitude or gradual JNK response. To test this hypothesis, we generated patient-specific models by incorporating gene expression data from three cohorts of primary neuroblastoma samples (table S3) ; a training cohort of 109 patients, and two independent validation cohorts of 369 patients, and 233 patients. Although the correlation between mRNA and protein abundance is weakly positive on a global scale (41), our analysis of multiple datasets consistently provided a strong correlation for all proteins within our model ( fig. S5A , B, C). Indeed, each of the transcripts and proteins exhibited correlation coefficients ≈ 0.6 and proportionality factors ≈ 1 (text S2: Rationale for using measured mRNA abundances as proxy for protein abundances, table S4, table S5 ).
Therefore, we adjusted the protein concentrations in the model for each patient, according to the relative gene expression measured in the tumor ( fig. S6A, Fig. 5A, fig. S7A ), for example, if the tumor sample showed a 2-fold increase of MKK4 mRNA, then we increased the abundance of MKK4 by 2-fold in the model. Following this procedure for all model components and for each patient resulted in personalized models that incorporated protein abundance based on the measured gene expression of ZAK, MKK4, MKK7, JNK (average of MAPK8, MAPK9, MAPK10 probes) and AKT (average of AKT1 and AKT2 probes).
Having generated these personalized models of the JNK stress response for each patient, we characterized these dynamic responses by extracting three JNK network output descriptors: the maximal amplitude (A), the activation threshold (K 50 To further examine the association between our model of JNK activation and disease progression, we stratified the patient population into two groups according to their simulated JNK network output descriptors. To identify the optimal cut-off values that best correlate or anticorrelate with survival for each output descriptor, we applied Kaplan-Meier scanning (42) to the training cohort ( fig. S6E ). Briefly, we sort the patients according to each output descriptor, start by putting 10% of patients into the low group and 90% into the high group, and then calculating the logrank test p-value in iterative steps. In each step, the size of the low group is increased by one patient. The best cut-off is the value of the output descriptor with the lowest p-value. This patient stratification process establishes the values that can be used to statistically significantly associate survival with Hill exponent, maximal amplitude, or threshold for JNK activation. Plotting the corresponding Kaplan-Meier survival curves showed a significant association between poor patient survival and low amplitude, low Hill exponent, or high threshold of JNK activation ( fig. S6E ). We then applied the same cutoffs to the independent validation cohorts and found the same association between an impaired JNK response and poor overall survival (Fig. 5E, fig. S7E ).
Notably, the Hill exponent, which measures the ultrasensitivity of the JNK response, provided the most accurate patient stratification. These results suggested that impairment of the JNK stress response, resulting from alterations in the concentration of kinases within the JNK network, contributes to a negative outcome for neuroblastoma patients.
JNK network alterations induced upon MYCN amplification
Because MYCN is the major oncogene driving neuroblastoma (19) , we hypothesized that MYCNamplified tumors may have altered JNK stress response dynamics. Inspection of each kinase within our model revealed that the most prominent changes in MYCN-amplified tumors were decreased MKK4 and increased ZAK and AKT (Fig. 6A ), all of which would be expected to impair JNK responses according to our model and experimental observations. Indeed, model simulations showed that MYCN-amplified patients exhibited markedly impaired JNK responses when compared to patients without MYCN amplification, with significant alterations in all three output descriptors of the JNK network ( Fig. 6B,C) .
These coordinated changes in the transcripts for the JNK network kinases and their association with MYCN amplification suggested that an impaired JNK response may be characteristic of MYCN-amplified tumors and may contribute to the innate chemoresistance associated with this aggressive form of neuroblastoma (19, 43) .
Despite this potential for MYCN to drive changes that impair the JNK response, a substantial number of patients lacking MYCN amplification also exhibited an impaired JNK response in our simulations. We, therefore, asked whether our model could also predict possible MYCN-independent effects on overall survival by performing survival analysis for the MYCN-nonamplified and MYCN-amplified groups separately. Under these conditions and considering p < 0.01 significant, only the Hill exponent was significantly associated with overall survival for both the MYCN-amplified and non-amplified patients when using cut-offs derived from the calibration cohort (Fig. 6D, fig. S8A, B ). However, when the optimal cut-offs were re-evaluated for each subcohort (MYCN-amplified and nonamplified) separately, all calculated network output characteristics of an impaired JNK response were significantly associated with poor patient survival in the nonamplified cohort ( fig. S8A ). For MYCN-amplified patients, the Hill exponent was significantly associated with poor survival (fig. S8B ), and the amplitude (p=0.026) came close to reaching our significance threshold (p<0.01). Thus, our modelling approach has confirmed that an impaired JNK response is significantly associated with poor survival in both MYCN-amplified andnonamplified cases.
We further tested whether using the model improves the current prognostic understanding based on wellestablished markers, such as MYCN status, age and stage (International Neuroblastoma Staging System, INNS) or risk (Children's Oncology Group, COG). Using several Cox proportional hazard analyses correcting for each marker in different combinations, we found that the dynamic model reliably contributed to predicting the overall survival (Table 1) . Individually as independent variables in a univariate analysis, maximum amplitude, H exponent, and threshold for JNK activation all significantly predicted overall survival. When combined with other markers in multivariate analysis, only A and H, but not K 50 , were independent prognostic indicators.
Robustness of the JNK dynamics and prognostic predictions
To determine whether the network model increased the amount of obtainable information or merely MKK4 showed the strongest correlation with overall survival and was more significantly associated with poor overall survival than our modelling analysis in the whole patient cohort. We, therefore, investigated the contribution of MKK4 to our modelling analysis in more detail. A sensitivity analysis of the model confirmed that changing the concentration of MKK4 markedly affected the JNK response (Fig. 7A) .
Although MKK7 and JNK were the most sensitive parameters with respect to equally sized perturbations ( Fig. 7A left, fig. S10A ), MKK4 was the most sensitive when the perturbation size was corrected for the variability observed in the tumor data ( Fig. 7A right) , and had the predominant effect on shaping both the JNK timecourse and dose response ( fig. S10B ). This suggested that, although MKK4 does not play a dominant role within this network structure, the abundance of MKK4 in the tumors is more markedly altered than that of the other model components. Accordingly, MKK4 contributed independently in a multivariate Cox regression analysis using MYCN amplification, age, and all kinases in the model as covariates (Table 2 ). However, whereas MKK4 expression was associated with survival in the whole patient cohort, when analyzing only MYCN-amplified or high risk patients the model outperformed the predictive capabilities of MKK4 (Fig. 6B ). Indeed, in the MYCN-amplified cohort, the model outperformed the predictive capacity of any of the individual components in the model (compare fig. 5D and fig. S9C ).
These cohort-specific associations suggest that placing these individual signaling pathway components into their network context is a necessary step for obtaining personalized simulations that can deliver robust predictions against different molecular backgrounds. This importance of network wiring was particularly highlighted by performing the patient simulations after removal of the positive feedback from within our model ( fig. S10C ). This analysis resulted in a substantial decrease in heterogeneity of the simulated patient responses for both the amplitude and Hill exponent (Fig. 7C) , and a complete loss of the prognostically relevant variability across the disease stages for the K 50 values and the Hill exponent (Fig.  7D ). The loss of stage-specific variation in JNK ultrasensitivity is of particular note given that the Hill exponent provided the most accurate stratification of the MYCN-amplified cohort. Further, it suggested that the JNK-MKK7 positive feedback enhances the overall impact of small alterations in the abundance of network components, thereby boosting the dynamic network response and leading to the generation of biologically meaningful response changes that ultimately influence patient survival.
Discussion
Our experimental characterization and personalized modelling of stress-induced JNK activation highlights the central role of JNK signaling in neuroblastoma patient outcome. The identification of major genetic alterations in JNK network components in breast and pancreatic cancer (44) (45) (46) further suggests that preventing JNK activation is a vital step during tumor progression and may ultimately be achieved through diverse mechanisms. Here, we identified mechanisms through which alterations in the transcript abundance and, thus, protein abundance of JNK network components result in impaired ultrasensitive JNK activation in neuroblastoma cells. The importance of these mechanisms is also supported by other studies that identified the ZAK-MKK4/MKK7-JNK module as a crucial mediator of apoptotic signaling in multiple cell types (24, 25, 47) . Indeed, studies have implicated the off-target inhibition of ZAK by inhibitors of the MAPKKK BRAF as a mechanism of chemoresistance in BRAF-mutant melanoma cells (48, 49) .
The importance of adopting a modelling approach when investigating the connections within a signaling network and implications for disease is highlighted by the prognostic significance of the patient-specific simulations from tumors with MYCN amplification. In this cohort, the simulation of JNK activation was significantly associated with overall survival, whereas none of the survival analyses performed with individual model components reached significance. Further refinement of this patient-specific modelling approach could certainly be achieved by using protein-based data (for example, reverse phase protein array), particularly regarding the inclusion of direct measurements of AKT phosphorylation. However, the ability of the model to achieve prognostic significance based upon simulations performed using gene expression data lends credence to the strength of this modelling approach and also is more practical for clinical application, because mRNA expression analysis is more common than RPPA.
The identification of a positive feedback loop from JNK to MKK7, facilitating the switch-like activation of JNK within our model, provides a potential mechanism for many experimental observations of ultrasensitive JNK activation (12, 14, 15) . Additionally, the combination of this positive feedback and patient-to-patient variation in the expression of transcripts encoding the JNK network components also underpins the prognostically significant heterogeneity in the patient-specific simulations JNK activation.
So far, it has been unclear how quantitative changes of expression might contribute to response variability, cell fate, and survival, because small changes might be statistically significant, but not biologically meaningful. Here, we demonstrated that many small changes distributed across the kinases within the JNK pathway synergize to evoke biologically meaningful response differences that translate into differences in patient survival. Small variations at the level of gene expression are enhanced at the level of pathway activation by the positive feedback that we identified within the JNK pathway.
Interestingly, the response heterogeneity introduced by the positive feedback from JNK to MKK7 contrasts with the related ERK pathway, in which negative feedback from ERK to RAF-1 increases robustness to perturbations and fluctuations in protein abundance (50, 51) . These findings highlight the vital role of compiling detailed information about network wiring in the development of computational models of signaling pathways. Even highly related pathways are not necessarily wired in a similar fashion, and any assumptions need to be carefully validated in order to derive biochemically correct and clinically relevant information. . Computational modelling has already provided an understanding of the dynamics of signaling pathways (16, (52) (53) (54) . Here, we showed that modelling approaches can not only be used to decipher and understand the behavior of complex networks on the cellular level but that they also can be used to relate biochemical pathway behavior to clinical outcomes on the level of individual patients. The simulation of patient-specific apoptotic JNK network responses provides an important proof-of-principle for the potential prognostic utility of experimentally resolved models of signaling networks, as opposed to biomarkers that lack this detailed mechanistic anchoring. The crucial advantage of a mechanistic model in this setting is that it can be quickly adapted to compare and predict the efficacy of different therapeutic agents once their mode of action has been determined.
Materials and Methods
Study Design
This study used the SH-SY5Y, SMS-KCN, and IMR32 neuroblastoma cells lines to generate, calibrate, and validate a mathematical model of stress-induced JNK signaling. Patient-specific simulations of JNK signaling were performed using three existing independent patient cohorts (55) . The training cohort comprised 109 international patients, the first validation cohort comprised 369 German patients, and the second validation cohort comprised 233 international patients (table S3) . 
Cell Lines.
The SH-SY5Y, SMS-KCN, and IMR-32 neuroblastoma cell lines have been described previously (59) .
These cell lines were cultured in standard RPMI 1640 (containing D-Glucose at 2 g/L) under standard tissue culture conditions (5% CO 2 , 20% O 2 ).
Site-Directed Mutagenesis.
Site-directed mutagenesis of MKK7 was performed using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent) according to manufacturer's instructions. The following primers were used for human MKK7; T66A forward primer 5'-gcagcaccccgcgccccccgc-3', T66A reverse primer 5'gcggggggcgcggggtgctgc-3'. T83A forward primer 5'-catgctgcggggtgcgaacagggttgacg-3', T83A reverse primer 5'-cgtcaaccctgttcgcaccccgcagcatg-3'. T385A forward primer 5'-caagcgctacgaggcgctggaggtgga-3', T385A reverse primer 5'-tccacctccagcgcctcgtagcgcttg-3'. The following primers were used for murine MKK7; T66A forward primer 5'-ccacagcaccctgcaccccccaccc-3', T66A reverse primer 5'gggtggggggtgcagggtgctgtgg-3'. T83A forward primer 5'-gctcccatcaaccttgttcgcaccgcgcagtat-3', T83A reverse primer 5'-atactgcgcggtgcgaacaaggttgatgggagc-3'. siRNA and shRNA.
The MKK4 (L-003574-00-0005), ZAK (L-005068-00-0005) JIP1 (L-003595-00-0005), JIP2 (L-012462-00-0005), JIP3 (L-003596-00-0005), JIP4 (L-017462-00-0005), and Negative Control (D-001810-10-05)
ONTARGET plus smartpool siRNAs were from Thermo-Fisher. The MKK7 SilencerSelect siRNA (s11184) was from Ambion. Transfection of siRNA was performed using the jetPRIME reagent (Polyplus Transfection) according to manufacturer's instructions. The pLKO control shRNA and pLKO ZAK shRNA (Clone name: NM_016653.x-362s1c1) plasmids were a kind gift from Prof William Gallagher (Conway Institute, University College Dublin). Plasmid transfection was performed using the jetPRIME reagent (Polyplus Transfection) according to manufacturer's instructions, and stable cell line selection performed with puromycin (2 μg/mL).
Western blotting and Immunoprecipitation.
Lysates for Western blotting and immunoprecipitation were prepared using normal lysis buffer (10 mM Tris-HCl pH 7.5, 140 mM NaCl, 1% Triton-X) containing protease inhibitor cocktail (p8340, Sigma) and
PhosSTOP Phosphatase Inhibitor Cocktail (Roche). Immunoprecipitation was performed using either GFP-Trap_A (Chromotek), V5 monoclonal antibody-coupled agarose beads or FLAG-M2-coupled magnetic beads (Sigma) as indicated. SDS-PAGE electrophoresis and Western blotting were performed using the NuPAGE SDS PAGE Gel System and NuPAGE Bis Tris Precast Gels (10% and 4-12%) (Life Technologies). SuperSignal West Femto Chemiluminescent Substrate (Thermo-Scientific) was used to develop Western blots, which were imaged using an Advanced Molecular Vision chemiluminescent imaging system. Quantitative Western blotting was performed using multistrip Western blotting (60) .
Cell-Based Assays.
Apoptosis was measured by propidium iodide staining and flow cytometric analysis to identify the subG1 population, as previously described (61) . Analysis was performed using an Accuri C6 flow cytometer (BD). Cytotoxicity assays were performed using the CellTiter 96 AQueous One Solution Cell Proliferation Assay according to manufacturer's instructions (Promega).
Dynamic Modelling.
Based on the experimentally resolved network structure depicted in Fig. 4A , a dynamic model was constructed by rule-based modelling (34) , which develops the ODEs based on a framework of rules describing the reactions and states of the system. The modelling is described in detail in the Extended Experimental Procedures. An extended contact map provides a graphical representation of this rule based model ( fig. S11) . A full account of all rules, equations, and parameters is provided in Table S1. The model was implemented in Matlab using the PottersWheels toolbox, which was also used for parameter estimation using adaptive simulated annealing as an optimizer. Table S2 contains 
Measuring mRNA expression in neuroblastoma tumor samples.
Sample set composition, sample preparation, and generation of single-color gene-expression profiles from primary neuroblastomas were described previously (62) .
Kaplan-Meier survival analysis
The best cut-off for stratifying the patient population into a low and high group was identified in the training cohort (109 patients) by scanning the group-sizes from 10-90 to 90-10 percent splits, where 10-90 means that 10% of the patients were in the low group and 90% of the patients in the high group and calculating the p-value for the overall survival difference between the groups using a log-rank test with Yates correction. These optimized cut-off values were then applied to the independent validation cohort (369 patients). Additionally, the optimal cut-offs were also re-derived in the validation set for the separate data are mean ± SD, n=3; simulations are mean ± SD, n=50. Contr, control; JNK inh., JNK inhibitor; si contr, siRNA control; si MKK4 or siMKK7, siRNA for MKK4 or MKK7; Ani, anisomycin; unstim., unstimulated (not exposed to stress-inducing drug). 
